CCR2 and neoplasm: Tu et al. demonstrated that combination therapy involving CCR2 antagonism and anti-programmed cell death protein 1 (PD-1) antibody suppresses primary tumor growth and lung metastasis in several murine tumor models by activating antitumor immune responses [53].